Back to today’s briefing

Story perspectives

Weight-Loss Retention 75-79% on GLP-1 vs 38-49% Placebo

5/24/2026

31 4

Summary

Story summary

Dr. Louis J. Aronne led ATTAIN-MAINTAIN trial, randomizing 376 adults at 29 U.S. sites to GLP-1 orforglipron or placebo for 52 weeks after 72 weeks of tirzepatide or semaglutide.
Tirzepatide and semaglutide switchers retained 75 % and 79 % of loss on the pill versus 49 % and 38 % on placebo.
Both groups ended the year at about 211 pounds, with GI side effects in under 5 % and 5-7 % stopping the pill, one death.

1 of 1

Story summary

Dr. Louis J. Aronne led ATTAIN-MAINTAIN trial, randomizing 376 adults at 29 U.S. sites to GLP-1 orforglipron or placebo for 52 weeks after 72 weeks of tirzepatide or semaglutide.
Tirzepatide and semaglutide switchers retained 75 % and 79 % of loss on the pill versus 49 % and 38 % on placebo.
Both groups ended the year at about 211 pounds, with GI side effects in under 5 % and 5-7 % stopping the pill, one death.